Medindia

X

VIVUS Announces Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea

Thursday, January 7, 2010 Research News J E 4
Advertisement
Qnexa Treatment Results in 69% Reduction in Sleep Apnea Events

CONTACT:  

VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris

Brian Korb

Chief Financial Officer

646-378-2923

650-934-5200

Media Relations:

Pure Communications, Inc.

Dan Budwick

973-271-6085

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
National Council on Disability to Make Housing Rec...
S
Sopherion Therapeutics Receives FDA Fast Track Des...